Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

The following is a summary of “Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations,” published in the February 2025 issue of the International Journal of ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...

Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...

Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company focusing on precision oncology treatments, announced today that it has entered into financial agreements to potentially increase its capital.

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” ...

Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced it will present positive results from the pivotal ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...